Strategie di mercato della pancreatite acuta, principali attori, opportunità di crescita, analisi e previsioni entro il 2030

The acute pancreatitis market size is projected to reach US$ 8,827.37 million by 2030 from US$ 5,649.77 million in 2022. The market is expected to register a CAGR of 5.7% during 2022–2030. Advancements in specific acute pancreatitis treatments are likely to serve as one of the key trends in the market.

Acute Pancreatitis Market Analysis

Several factors fuel the acute pancreatitis market growth, including the rising prevalence of diabetes, advances in diagnostic tools, and the development of novel treatment options. Obesity, consumption of alcohol, gallstones, and some medications have collectively contributed to a rise in the incidence of acute pancreatitis globally. Key market players invest in clinical trials, strategic alliances, and collaborations to strengthen their product portfolios and acquire a competitive advantage. The industry is being pushed by rising prevalence and demand for better treatment options. Ongoing research and development efforts and collaborative approaches are also expected to foster innovation and enhance outcomes for acute pancreatitis patients, thereby boosting the growth of the acute pancreatitis market during the forecast period.

Acute Pancreatitis Market Overview

A targeted novel treatment strategy that halts disease progression and improves patient outcomes is needed to address the current disease burden of acute and severe acute pancreatitis. An article published in the National Library of Medicine in February 2023 focuses on three major approaches to advance acute pancreatitis treatments—the clinical identification and application of new genetic information; newly identified serum biomarkers, i.e., fatty acid ethyl esters (FAEEs); and acceleration in timing of early nutrition feedings in acute pancreatitis. Such developments in specific treatment approaches would lead to new treatment options to enhance outcomes and improve the acute pancreatitis market during the forecast period.

Acute Pancreatitis Market:

Personalizza questo rapporto in base alle tue esigenze

Potrai personalizzare gratuitamente qualsiasi rapporto, comprese parti di questo rapporto, o analisi a livello di paese, pacchetto dati Excel, oltre a usufruire di grandi offerte e sconti per start-up e università

Ottieni la PERSONALIZZAZIONE GRATUITA

Mercato della pancreatite acuta: Approfondimenti strategici

• Ottieni le principali tendenze chiave del mercato di questo rapporto.
  Questo campione GRATUITO includerà l'analisi dei dati, che vanno dalle tendenze di mercato alle stime e alle previsioni.

PDF di esempio gratuito

Acute Pancreatitis Market

• 
  CAGR (2022 - 2030)

  5.7%
• Market Size 2022
  US$ 5,649.77 Million
• Market Size 2030
  US$ 8,827.37 Million

Market Dynamics

GROWTH DRIVERS

• Rising Incidence of Diabetes

FUTURE TRENDS

• Advancements in Specific Acute Pancreatitis Treatments

OPPORTUNITIES

• Upsurge in Awareness Programs on Acute Pancreatitis

Key Players

• Abbott Laboratories
• GE HealthCare Technologies Inc
• Samsung Healthcare
• Koninklijke Philips NV
• Baxter International Inc
• Dynavax Technologies Corp
• Actim Oy
• Medtronic Plc
• Boston Scientific Corp
• Fresenius Kabi AG

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Offerings

• Medications
• Diagnosis
• Others

Causes

• Gallstones
• Alcoholism
• Genetic Disorders
• Infections
• Others

End User

• Hospitals
• Diagnostic Laboratories
• Ambulatory Surgical Centers
• Others

Acute Pancreatitis Market Drivers and Opportunities

Rising Incidence of Diabetes Following Acute Pancreatitis to Favor Market Growth

The pancreas produces insulin, a hormone that regulates blood sugar levels. Pancreatitis can harm insulin-producing cells of the pancreas, which causes diabetes in patients suffering from acute pancreatitis. Pancreatogenic diabetes is increasingly being linked to exocrine disorders of the pancreas. As per the European Review for Medical and Pharmacological Sciences, published in 2022, the prevalence of pancreatogenic diabetes is 5–10% in the Western diabetic population, and chronic pancreatitis is responsible for 20% of cases, while acute pancreatitis causes 80% of cases. According to an article published in the National Library of Medicine in 2021, ~23% of acute pancreatitis patients are likely to develop diabetes within three years of discharge. Thus, the increasing incidence of diabetes in patients suffering or recovering from acute pancreatitis contributes to the growth of the acute pancreatitis market.

Upsurge in Awareness Programs on Acute Pancreatitis

Several ongoing international efforts are being made to define the epidemiology and pathophysiology of acute pancreatitis. The National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) formed a collaborative network of 10 clinical centers and 1 data coordination center in 2020 to address several knowledge gaps regarding acute pancreatitis. The consortium is referred to as Type 1 Diabetes after Acute Pancreatitis Consortium (T1DAPC). Thus, awareness programs on acute pancreatitis for the development of effective therapies (through direct and indirect means) are expected to provide lucrative opportunities for companies in the acute pancreatitis market.

Acute Pancreatitis Market Report Segmentation Analysis

Key segments that contributed to the derivation of the acute pancreatitis market analysis are offerings, causes, and end user.

• Based on offerings, the acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest share of the market in 2022. The others segment is anticipated to register the highest CAGR during the forecast period.
• In terms of causes, the market is categorized into gallstones, alcoholism, genetic disorders, infections, and others. The gallstones segment held the largest share of the market in 2022 and is projected to register the fastest CAGR during the forecast period.
• Based on end user, the market is segmented into hospitals, diagnostic laboratories, ambulatory surgical centers, and others. The hospitals segment held the largest share of the market in 2022. The diagnostic laboratories segment is estimated to register the fastest CAGR during the forecast period.

Acute Pancreatitis Market Share Analysis by Geography

The geographic scope of the acute pancreatitis market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has dominated the acute pancreatitis market. The growth of the market in this region is attributed to a high incidence of risk factors such as obesity and consumption of alcohol, modern healthcare infrastructure, and strong government campaigns promoting early detection and treatment. According to the 2021 National Survey on Drug Use and Health, ~174.3 million people in the US aged 12 and above consumed alcohol in 2020. According to Medscape data, ~40–50 acute pancreatitis cases per 100,000 adults are registered in the US annually. Nearly 275,000 hospital admissions in the US are due to acute pancreatitis. In addition, the region also has several key market players, such as pharmaceutical corporations and medical device manufacturers, who are actively involved in research and development to create innovative new and novel products in the market, thereby supporting the market growth in the region. Further, Asia Pacific is projected to grow with the highest CAGR in the coming years.

Acute Pancreatitis

Acute Pancreatitis Market News and Recent Developments

The acute pancreatitis market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the acute pancreatitis market are listed below:

• Arrivo BioVentures announced that the Food and Drug Administration (FDA) has granted its subsidiary, Panafina Inc., Fast Track designation for its investigational new drug, RABI-767, for the treatment of acute pancreatitis predicted to progress to severe disease. RABI-767 is an investigational small-molecule lipase inhibitor that is administered by endoscopic ultrasound-guided peripancreatic injection. RABI-767 is currently being evaluated in a phase 2a trial in patients predicted to develop severe acute pancreatitis. (Source: Arrivo BioVentures, Press Release, July 2024)
• CalciMedica Inc. announced that its collaborator, St. Jude Children's Research Hospital (SJCRH), presented data from the initial cohort of the Phase 1/2 CRSPA study of Auxora (zegocractin injectable emulsion) in asparaginase-induced pancreatic toxicity (AIPT) at the 65th Annual American Society of Hematology (ASH) Meeting & Exposition on December 2023, in San Diego, CA. (Source: CalciMedica Inc., Press Release, December 2023)

Acute Pancreatitis Market Report Coverage and Deliverables

The “Acute Pancreatitis Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:

• Acute pancreatitis market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Acute pancreatitis market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST and SWOT analysis
• Acute pancreatitis market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the acute pancreatitis market
• Detailed company profiles

Responsabile della ricerca

Mrinal Kelhalkar

Manager,
Ricerca e consulenza

Mrinal è un'analista di ricerca esperta con oltre 8 anni di esperienza nella consulenza e nell'intelligence di mercato nel settore delle scienze biologiche. Grazie a una mentalità strategica e a un costante impegno verso l'eccellenza, ha maturato una profonda competenza nelle previsioni farmaceutiche, nella valutazione delle opportunità di mercato e nello sviluppo di benchmark di settore. Il suo lavoro è incentrato sulla fornitura di insight fruibili che consentono ai clienti di prendere decisioni strategiche consapevoli.

Il punto di forza di Mrinal risiede nella capacità di tradurre complessi set di dati quantitativi in ​​business intelligence significative. Il suo acume analitico è fondamentale per definire strategie di go-to-market (GTM) e individuare opportunità di crescita nei settori farmaceutico e dei dispositivi medici. In qualità di consulente di fiducia, si concentra costantemente sulla semplificazione dei processi di flusso di lavoro e sulla definizione di best practice, promuovendo così l'innovazione e l'efficienza operativa per i suoi clienti.

Testimonianze

Il report di mercato sui sistemi SCADA di Insight Partners è completo, con preziosi spunti sulle tendenze attuali e sulle previsioni future. Il team si è dimostrato altamente professionale, reattivo e disponibile in ogni fase del progetto. Siamo molto soddisfatti e consigliamo vivamente i loro servizi.

RAN KEDEM Partner, Reali Technologies LTDs

Ho richiesto un report su un mercato software molto specifico e il team lo ha prodotto in pochi giorni. Le informazioni erano molto pertinenti e ben presentate. Ho quindi richiesto alcune modifiche e aggiunte al report. Il team è stato ancora una volta molto reattivo e ho ricevuto il report finale in meno di una settimana.

JEAN-HERVE JENN Presidente, Future Analytica

Abbiamo collaborato con The Insight Partners per un importante studio di mercato e una previsione. Ci hanno fornito informazioni chiare su opportunità e rischi, che ci hanno aiutato a definire i nostri piani. La loro ricerca è stata facile da usare e basata su dati solidi. Ci ha aiutato a prendere decisioni intelligenti e consapevoli. Li consigliamo vivamente.

PIYUSH NAGPAL Vicepresidente senior, Abbaglianti globali

Insight Partners ha fornito ricerche di mercato approfondite e ben strutturate, con una solida competenza nel settore. Il loro team si è dimostrato professionale e reattivo in ogni fase. Il sito web intuitivo ha reso l'accesso ai report di settore semplice e immediato. Li consigliamo vivamente per servizi di ricerca affidabili e di alta qualità.

YUKIHIKO ADACHI Amministratore delegato, Deep Blue, LLC.

Questa è la prima volta che acquisto un report di mercato da The Insight Partners. Sebbene inizialmente fossi indeciso, ho visitato il loro sito web e mi sono sentito più a mio agio nell'acquistare un report di mercato. Sono completamente soddisfatto della qualità del report e del servizio clienti. Avevo diverse domande e commenti sul report iniziale, ma dopo un paio di conversazioni via email con il loro analista credo di avere un report che posso utilizzare come input per il nostro processo di pianificazione strategica. Grazie mille per aver dedicato del tempo extra e aver reso questa esperienza positiva. Consiglierò sicuramente il vostro servizio ad altri e sarete la mia prima persona a cui rivolgermi quando avremo bisogno di ulteriori dati di mercato.

GIOVANNI SUZUKI Presidente e Amministratore Delegato, Consigliere di Amministrazione, Tecnologie BK

Desidero esprimere la mia gratitudine per il supporto e la professionalità dimostrati nel rispondere alla mia richiesta di informazioni sul mercato dei dispositivi medici in vitro per malattie infettive in Nigeria. Apprezzo la vostra pazienza, la vostra guida e la vostra disponibilità a offrirmi uno sconto, che alla fine ci ha permesso di concludere l'affare. Non vedo l'ora di collaborare con The Insight Partners in futuro, grazie anche all'impressione che mi avete lasciato dopo questo primo incontro.

Dott. Chijioke AMMINISTRATORE DELEGATO DI ONYIA, PineCrest Healthcare Ltd.

Previous Next